However, there is currently no base editor to directly edit G or T, since deamination of G rarely causes base conversion, while T lacks amino groups, making it a challenge to overcome the limitation and develop a new class of base editors. Therefore, there is still a need to edit G or T in many cases.
HuidaGene Therapeutics, a clinical-stage genome-editing company, says the National Science Review has published data from its study of the world’s first DNA base editor converting guanine to cytosine/thymine (pyrimidine), or G-to-Y.
The company has filed an international patent application for the glycosylase-based guanine base editor (gGBE) and owns the exclusive global rights to the underlying patent.
Current widely-used DNA base editors mainly integrate programmable DNA binding proteins (Cas9, Cas12, or TALE protein variants) with base deaminases (cytidine deaminase or adenosine deaminase variants). There are mainly two types of base editors: ABE (adenine base editor) and CBE (cytosine base editor), which can realize A-to-G and C-to-T transition between bases 1–2.
A new study led by investigators from Mass General Brigham has found that ChatGPT was about 72 percent accurate in overall clinical decision making, from coming up with possible diagnoses to making final diagnoses and care management decisions. The large-language model (LLM) artificial intelligence chatbot performed equally well in both primary care and emergency settings across all medical specialties. The research team’s results are published in the Journal of Medical Internet Research.
Our paper comprehensively assesses decision support via ChatGPT from the very beginning of working with a patient through the entire care scenario, from differential diagnosis all the way through testing, diagnosis, and management. No real benchmarks exists, but we estimate this performance to be at the level of someone who has just graduated from medical school, such as an intern or resident. This tells us that LLMs in general have the potential to be an augmenting tool for the practice of medicine and support clinical decision making with impressive accuracy.
Summary: Researchers successfully sequenced the entire Y chromosome, previously considered the most elusive part of the human genome.
This feat enhances DNA sequencing accuracy for this chromosome, aiding the identification of genetic disorders. Using state-of-the-art technologies, the team pieced together over 62 million letters of genetic code.
This breakthrough, in tandem with the previous reference genome T2T-CHM13, offers the first complete genome for those with a Y chromosome.
A new efficient system of cancer treatment using vitamin k3 (Vk3)-loaded copper zinc ferrite nanoparticles having therapeutic capabilities, could benefit millions of cancer patients worldwide.
With the ever-increasing prevalence of cancer cases worldwide, newer approaches to cancer therapy are increasingly needed to tackle the problem. Since conventional cancer therapies such as chemotherapy, radiation therapy and surgery have significant drawbacks such as resistance to chemotherapeutic drugs, adverse effects and lower efficacy, development of nanotherapies that can target hypoxic (when oxygen is not available in sufficient amounts at the tissue level) tumors, with minimum side-effects is necessary.
At present, magnetic hyperthermia-based cancer therapy (MHCT) therapy has been shown to be therapeutic. However, in most cases, it is not as effective due to the generation of lower levels of reactive oxygen species (ROS) in a hypoxic tumor microenvironment (TME) and low heat transmission.
Researchers from the University of Cambridge have unveiled a surprising discovery that holds the potential to reshape the landscape of electrochemical devices. This new insight opens the door for the creation of cutting-edge materials and paves the way for enhancements in sectors like energy storage, neuromorphic computing, and bioelectronics.
Electrochemical devices rely on the movement of charged particles, both ions, and electrons, to function properly. However, understanding how these charged particles move together has presented a significant challenge, hindering progress in creating new materials for these devices.
In the rapidly evolving field of bioelectronics, soft conductive materials known as conjugated polymers are used for developing medical devices that can be used outside of traditional clinical settings. For example, this type of material can be used to make wearable sensors that monitor patients’ health remotely or implantable devices that actively treat disease.
Dr. Joni L. Rutter, Ph.D., (https://ncats.nih.gov/director/bio) is the Director of the National Center for Advancing Translational Sciences (NCATS — https://ncats.nih.gov/) at the U.S. National Institutes of Health (NIH) where she oversees the planning and execution of the Center’s complex, multifaceted programs that aim to overcome scientific and operational barriers impeding the development and delivery of new treatments and other health solutions. Under her direction, NCATS supports innovative tools and strategies to make each step in the translational process more effective and efficient, thus speeding research across a range of diseases, with a particular focus on rare diseases.
By advancing the science of translation, NCATS helps turn promising research discoveries into real-world applications that improve people’s health. The NCATS Strategic Plan can be found at — https://ncats.nih.gov/strategicplan.
In her previous role as the NCATS deputy director, Dr. Rutter collaborated with colleagues from government, academia, industry and nonprofit patient organizations to establish robust interactions with NCATS programs.
Prior to joining NCATS, Dr. Rutter served as the director of scientific programs within the All of Us Research Program, where she led the scientific programmatic development and implementation efforts to build a national research cohort of at least 1 million U.S. participants to advance precision medicine. During her time at NIH, she also has led the Division of Neuroscience and Behavior at the National Institute on Drug Abuse (NIDA). In this role, she developed and coordinated research on basic and clinical neuroscience, brain and behavioral development, genetics, epigenetics, computational neuroscience, bioinformatics, and drug discovery. Dr. Rutter also coordinated the NIDA Genetics Consortium and biospecimen repository.
Throughout her career, Dr. Rutter has earned an international reputation for her diverse and unique expertise via her journal publications and speaking engagements, and she has received several scientific achievement awards, including the 2022 Rare Disease Legislative Advocates–RareVoice Award for Federal Advocacy and the 2022 FedHealthIT–Women in Leadership Impact Award.
Dr. Rutter received her Ph.D. from the Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire, and completed a fellowship at NCI within the Division of Cancer Epidemiology and Genetics.
The thyroid is a butterfly-shaped gland in your lower neck. It produces hormones that help regulate your metabolism, temperature and energy levels.
Thyroid cancer develops when cells within the thyroid mutate and grow abnormally. Thyroid cancer symptoms can be subtle early on and sometimes are blamed on an infection or a seasonal allergy. Thyroid cancer is highly treatable using a variety of methods.
Scientists use AI-powered brain-computer interface (BCI) to decipher speech.
Brain chips, a current research focus, are used for recording brain activity and treating several neurodegenerative diseases. In May this year, a man who lost the ability to talk because of a motorcycle incident stood up after 12 years thanks to brain implants that provided a bridge for communication between his brain and spinal cord.
Another area in which brain implants have shown significant potential is deciphering speech. Decoding brain signals to speech.
Gremlin/iStock.
In May this year, a man who lost the ability to talk because of a motorcycle incident stood up after 12 years thanks to brain implants that provided a bridge for communication between his brain and spinal cord.
To address the HIV surveillance needs of the global community, the Applied Biosystems HIV-1 Genotyping Kit with Integrase offers broad genotyping coverage of HIV-1 Group M subtypes from extracted viral RNA from plasma and dried blood spot (DBS) samples to detect resistance to protease inhibitors, nucleoside reverse-transcriptase inhibitors, non-nucleoside reverse-transcriptase inhibitors, and integrase inhibitors.
This HIV-1 resistance kit harnesses gold-standard Sanger sequencing technology to amplify and reliably sequence the diverse and rapidly evolving HIV-1 virus.
This product employs assays for HIV-1 genotyping licensed from the U.S. Centers for Disease Control and Prevention.
